These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 25004822)

  • 21. Block copolymer prodrugs: Synthesis, self-assembly, and applications for cancer therapy.
    Dutta D; Ke W; Xi L; Yin W; Zhou M; Ge Z
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jan; 12(1):e1585. PubMed ID: 31452353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
    Akinboye ES; Brennen WN; Rosen DM; Bakare O; Denmeade SR
    Prostate; 2016 Jun; 76(8):703-14. PubMed ID: 26835873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges?
    Kubizek F; Eggenreich B; Spadiut O
    Protein Pept Lett; 2017; 24(8):686-695. PubMed ID: 28741467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzyme/abzyme prodrug activation systems: potential use in clinical oncology.
    Nishi Y
    Curr Pharm Des; 2003; 9(26):2113-30. PubMed ID: 14529409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current prodrug design for drug discovery.
    Hsieh PW; Hung CF; Fang JY
    Curr Pharm Des; 2009; 15(19):2236-50. PubMed ID: 19601825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.
    Sharma SK; Bagshawe KD
    Expert Opin Biol Ther; 2017 Jan; 17(1):1-13. PubMed ID: 27737561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
    Huo M; Zhu Q; Wu Q; Yin T; Wang L; Yin L; Zhou J
    J Pharm Sci; 2015 Jun; 104(6):2018-2028. PubMed ID: 25820241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, Synthesis and Studies on Novel Polymeric Prodrugs of Erlotinib for Colon Drug Delivery.
    Kumar S; Sharma B; Bhardwaj TR; Singh RK
    Anticancer Agents Med Chem; 2021; 21(3):383-392. PubMed ID: 32781967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody directed enzyme prodrug therapy (ADEPT) and related approaches for anticancer therapy.
    Jung M
    Mini Rev Med Chem; 2001 Nov; 1(4):399-407. PubMed ID: 12369965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prodrugs in cancer chemotherapy.
    Connors TA; Knox RJ
    Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates.
    Huennekens FM
    Trends Biotechnol; 1994 Jun; 12(6):234-9. PubMed ID: 7765070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticancer platinum (IV) prodrugs with novel modes of activity.
    Chin CF; Wong DY; Jothibasu R; Ang WH
    Curr Top Med Chem; 2011; 11(21):2602-12. PubMed ID: 22039869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate.
    Smith GK; Banks S; Blumenkopf TA; Cory M; Humphreys J; Laethem RM; Miller J; Moxham CP; Mullin R; Ray PH; Walton LM; Wolfe LA
    J Biol Chem; 1997 Jun; 272(25):15804-16. PubMed ID: 9188478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy.
    Legigan T; Clarhaut J; Tranoy-Opalinski I; Monvoisin A; Renoux B; Thomas M; Le Pape A; Lerondel S; Papot S
    Angew Chem Int Ed Engl; 2012 Nov; 51(46):11606-10. PubMed ID: 22996951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent trends in targeted anticancer prodrug and conjugate design.
    Singh Y; Palombo M; Sinko PJ
    Curr Med Chem; 2008; 15(18):1802-26. PubMed ID: 18691040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficient enzyme-activated therapy based on the different locations of protein and prodrug in nanoMOFs.
    Wang F; Yang J; Li Y; Zhuang Q; Gu J
    J Mater Chem B; 2020 Jul; 8(28):6139-6147. PubMed ID: 32568339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzyme-catalyzed activation of anticancer prodrugs.
    Rooseboom M; Commandeur JN; Vermeulen NP
    Pharmacol Rev; 2004 Mar; 56(1):53-102. PubMed ID: 15001663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies.
    Tietze LF; Krewer B
    Chem Biol Drug Des; 2009 Sep; 74(3):205-11. PubMed ID: 19660031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging Strategies in Stimuli-Responsive Prodrug Nanosystems for Cancer Therapy.
    Ding C; Chen C; Zeng X; Chen H; Zhao Y
    ACS Nano; 2022 Sep; 16(9):13513-13553. PubMed ID: 36048467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiency.
    Lin MH; Hung CF; Hsu CY; Lin ZC; Fang JY
    Future Med Chem; 2019 Aug; 11(16):2131-2150. PubMed ID: 31538520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.